Whole-course drug therapy management method and system based on chronic kidney disease patient

Abstract

The invention relates to the field of drug therapy management, in particular to a whole-course drug therapy management method and system based on a chronic kidney disease patient, and the method comprises the steps: reading a kidney disease patient data set from a pre-constructed hospital database based on a patient ID, sending a pre-constructed medical intelligent medicine box to a patient address, the method comprises the following steps of: acquiring medicine taking compliance and settlement medicine boxes by using a medicine arrangement sequence and operation medicine boxes, calculating medicine inadequacy by using patient age, patient weight, an adverse reaction set and a patient management database, calculating state recovery degree by using basic body indexes, diagnosis body indexes, updated basic index sets and updated diagnosis indexes, and updating average indexes; and calculating a treatment success index according to the medicine taking compliance, the medicine inappropriate degree and the state recovery degree until the medicine treatment time is longer than the preset whole-course treatment time, and completing whole-course medicine treatment management on the chronic kidney disease patient. The accuracy and the automation degree of whole-course drug treatment management can be improved, and the burden of human resources of hospitals is relieved.

Description

Technical Field

[0001] This invention relates to the field of drug therapy management, and more particularly to a method, system, electronic device, and computer-readable storage medium for the comprehensive drug therapy management of patients with chronic kidney disease. Background Technology

[0002] Chronic kidney disease (CKD) is a common, progressive kidney failure disease. With the increasing number of kidney disease patients worldwide, effectively managing the drug therapy for CKD patients has become one of the major challenges in clinical treatment.

[0003] Treatment for chronic kidney disease typically involves using various medications to control disease progression and slow kidney damage. Management methods usually involve regular follow-ups by healthcare professionals or telephone communication to monitor and manage the medications of patients with chronic kidney disease.

[0004] While existing methods can manage the entire course of medication for patients with chronic kidney disease, they rely too heavily on manual supervision and management, and lack real-time, comprehensive monitoring of the patient's treatment process. This makes it difficult to comprehensively consider patient medication adherence and the incidence of adverse reactions. Therefore, improving the automation level of the entire course of medication management while considering the combined impact of medication adherence and adverse reactions, and reducing the burden on hospital human resources, has become an urgent problem to be solved. Summary of the Invention

[0005] This invention provides a method for managing the entire course of drug therapy for patients with chronic kidney disease and a computer-readable storage medium. Its main purpose is to improve the accuracy and automation of the entire course of drug therapy management and reduce the burden on hospital human resources.

[0006] To achieve the above objectives, the present invention provides a method for comprehensive drug treatment management of patients with chronic kidney disease, comprising:

[0007] Obtain the patient ID, and read the kidney disease patient dataset from the pre-built hospital database based on the patient ID. The kidney disease patient dataset includes: patient age, patient weight, patient address, basic physical indicators, diagnostic physical indicators and medication schedule. Starting from the time when the kidney disease patient dataset is read, the time is recorded in real time to obtain the drug treatment time.

[0008] The pre-built smart medical pillbox is sent to the patient's address. When the smart medical pillbox is signed for, an operational pillbox is obtained. The operational pillbox includes multiple ordinary pill compartments, and each ordinary pill compartment includes a pill compartment indicator light, a pill compartment number, and a pill compartment window.

[0009] Medication adherence and billing pillboxes are obtained by using drug arrangement sequence and pillbox operation. The billing pillboxes are then recycled to obtain empty pillboxes.

[0010] Based on the patient ID, the adverse reaction set, the updated basic indicator set, and the updated diagnostic indicators are retrieved from the pre-built patient management database. The adverse reaction set includes n adverse reaction groups, and each adverse reaction group includes an adverse reaction number and an adverse reaction time.

[0011] Drug inappropriateness was calculated using patient age, patient weight, adverse reaction set, and patient management database.

[0012] The status recovery degree and updated average index are calculated using basic physical indicators, diagnostic physical indicators, updated basic indicator set and updated diagnostic indicators.

[0013] The treatment success index is calculated based on medication adherence, medication inappropriateness, and recovery status. The target pillbox and target arrangement sequence are then identified based on the available pillboxes and the treatment success index.

[0014] The target pillbox is used as a medical smart pillbox, the target arrangement sequence is used as a drug arrangement sequence, the updated average index is used as a basic physical index, and the updated diagnostic index is used as a diagnostic physical index. The process returns to the step of sending the pre-constructed medical smart pillbox to the patient's address until the drug treatment time is longer than the preset total treatment time, thus completing the full-course drug treatment management for patients with chronic kidney disease.

[0015] Optionally, the method of obtaining medication adherence and settling accounts using drug delivery sequences and pillbox operation includes:

[0016] The system acquires the daily time in real time. When the daily time equals the preset start time, it extracts the first drug data from the drug arrangement sequence and marks the drug arrangement sequence after extracting the first drug data as a waiting arrangement sequence. The drug arrangement sequence includes multiple drug data, and the number of drug data in the drug arrangement sequence is equal to the number of ordinary drug compartments in the operating drug box. The drug data includes the drug reminder time and drug compartment number. The first drug data is the drug data that is ranked first in the drug arrangement sequence.

[0017] When the time of a single day is equal to the drug reminder time in the first drug data, ordinary drug warehouses with the same drug warehouse number as the drug warehouse number in the first drug data are marked as candidate drug warehouses;

[0018] Make the indicator light of the medicine warehouse in the candidate medicine warehouse flash, and obtain the flashing medicine warehouse. The time when the flashing medicine warehouse is obtained is taken as the starting point and the time is recorded in real time to obtain the flashing time.

[0019] The usage status of the medicine storage window corresponding to the flashing medicine storage is monitored in real time. The usage status includes: open state and closed state, and the initial state of the medicine storage window is closed.

[0020] When the medicine storage window is opened, the medicine storage indicator light of the flashing medicine storage stops flashing, indicating a successful medicine storage. The medication time is confirmed based on the flashing time, where the medication time is equal to the flashing time.

[0021] The medication time is recorded in a pre-constructed recording unit to obtain a statistical unit. It is then determined whether there is medication data in the waiting arrangement sequence. If there is medication data in the waiting arrangement sequence, the waiting arrangement sequence is used as the medication arrangement sequence, the statistical unit is used as the recording unit, and the process returns to the step of obtaining the daily time in real time.

[0022] When the flashing time reaches the preset reminder time threshold and the medicine warehouse window is closed, the medicine warehouse indicator light of the flashing medicine warehouse stops flashing, the failed medicine warehouse is obtained, and it is determined whether there is drug data in the waiting arrangement sequence. If there is drug data in the waiting arrangement sequence, the waiting arrangement sequence is used as the drug arrangement sequence, and the process returns to the step of real-time acquisition of daily time.

[0023] Until no drug data is found in the waiting arrangement sequence, the successful drug warehouses are aggregated to obtain multiple successful drug warehouses, and the failed drug warehouses are aggregated to obtain multiple failed drug warehouses. The number of multiple successful drug warehouses and the number of multiple failed drug warehouses are counted respectively to obtain the number of successes and the number of failures. Based on the multiple successful drug warehouses and the multiple failed drug warehouses, the settlement drug box is confirmed.

[0024] Multiple medication times are read from the statistical unit, and medication adherence is calculated based on the number of successful doses, the number of failed doses, and the multiple medication times.

[0025] Optionally, the formula for calculating medication adherence is as follows:

[0026]

[0027] Where, τ CKD Medication adherence is represented by α (number of successful cases), β (number of failed cases), and t (number of expenditures). i For the i-th medication time among multiple medication times, t max The reminder time threshold is given, and ln is the natural logarithm.

[0028] Optionally, the calculation of drug inappropriateness using patient age, patient weight, adverse reaction set, and patient management database includes:

[0029] Obtain the adverse reaction sequence, wherein the adverse reaction sequence includes: m adverse reaction numbers;

[0030] For each adverse reaction group in the adverse reaction set, the following procedures were performed:

[0031] Adverse reaction numbers that are identical to adverse reaction numbers in the adverse reaction sequence are identified as pending confirmation numbers, and the position of the pending confirmation number in the adverse reaction sequence is used as the adverse reaction position.

[0032] The adverse reaction coefficient is calculated based on the adverse reaction ranking and the adverse reaction time in the adverse reaction group, using the following formula:

[0033]

[0034] Where, p f Here, x represents the adverse reaction coefficient, and t represents the adverse reaction ranking. f This refers to the time of adverse reaction.

[0035] Summarize the adverse reaction coefficients to obtain n adverse reaction coefficients, and calculate the adverse reaction index based on the n adverse reaction coefficients, where the adverse reaction index is the sum of the n adverse reaction coefficients;

[0036] Based on the patient's age, an age range is determined. Based on the age range, N reference patient information is retrieved from the patient management database. The reference patient information includes: reference response set, reference weight, and reference age, and the reference age is within the age range.

[0037] For each of the N reference patient records, perform the following operation:

[0038] The reference response index is obtained based on the reference response set in the reference patient information.

[0039] By summing the reference response indices, N reference response indices are obtained;

[0040] Drug inappropriateness is calculated based on the adverse reaction index, N reference reaction indices, patient age, and patient weight.

[0041] Optionally, determining the age range based on the patient's age includes:

[0042] The maximum and minimum ages are calculated based on the patient's age and a preset similar age. The maximum age is the sum of the patient's age and the similar age, and the minimum age is the absolute difference between the patient's age and the similar age.

[0043] An age range is determined based on the maximum and minimum ages, where the maximum age is the maximum age and the minimum age is the minimum age.

[0044] Optionally, the calculation of drug inappropriateness based on the adverse reaction index, N reference reaction indices, patient age, and patient weight includes:

[0045] The target reference index is calculated based on N reference response indices, the patient's age, and the patient's weight, using the following formula:

[0046]

[0047] Where, μ x The target reference index is Y0, where Y0 is the patient's age, G0 is the patient's weight, and P is the target reference index. i Y is the i-th reference response index among N reference response indices. i and G i These are the reference age and reference weight corresponding to the i-th reference response index among N reference response indices, where | represents taking the absolute value;

[0048] Drug inappropriateness is calculated based on the adverse reaction index and the target reference index, using the following formula:

[0049]

[0050] Where, μ CKD For inappropriate medication, μ x This is the adverse reaction index.

[0051] Optionally, the step of calculating the state recovery degree and updating the average index using basic physical indicators, diagnostic physical indicators, an updated set of basic indicators, and updated diagnostic indicators includes:

[0052] The updated mean heart rate, updated mean blood glucose, and updated mean blood pressure are calculated based on the updated basic indicator set. The updated basic indicator set includes multiple updated indicators, and the updated indicators include updated heart rate, updated blood glucose, and updated blood pressure. The updated mean heart rate, updated mean blood glucose, and updated mean blood pressure are the average values ​​of the updated heart rate, updated blood glucose, and updated blood pressure corresponding to the multiple updated indicators, respectively.

[0053] The updated average indicators are obtained by summarizing and updating the average heart rate, average blood glucose, and average blood pressure.

[0054] Recovery status is calculated based on basic physical indicators, diagnostic physical indicators, updated average indicators, and updated diagnostic indicators. Basic physical indicators include: basic heart rate, basic blood glucose, and basic blood pressure. Diagnostic physical indicators include: serum creatinine level and parathyroid hormone level. Updated diagnostic indicators include: updated serum creatinine level and updated parathyroid hormone level. The formula for calculating recovery status is shown below:

[0055]

[0056] Where, θ CKD To indicate recovery status, HR0, BG0, and BP0 represent baseline heart rate, baseline blood glucose, and baseline blood pressure, respectively. and These represent the updated mean heart rate, updated mean blood glucose, and updated mean blood pressure, respectively, among the updated mean indicators. Cr0 and PTH0 represent serum creatinine and parathyroid hormone levels, respectively. x and PTH x These are the refreshed serum creatinine level and the refreshed parathyroid hormone level, respectively, HR best The preset optimal heart rate is defined as a0, the preset serum creatinine weight is b0, and the preset parathyroid hormone weight is b0.

[0057] Optionally, the formula for calculating the treatment success index is as follows:

[0058]

[0059] Among them, Tr CKD The success rate index is denoted by e, which is a natural constant.

[0060] Optionally, the step of identifying the target pillbox and target arrangement sequence based on available pillboxes and treatment success index includes:

[0061] The treatment success index is compared with a preset first treatment threshold and the treatment success index is compared with a preset second treatment threshold, wherein the first treatment threshold is greater than the second treatment threshold;

[0062] If the treatment success index is greater than or equal to the first treatment threshold, then obtain the health care arrangement sequence, and use the empty medicine box to obtain the health care medicine box, use the health care medicine box as the target medicine box, and use the health care arrangement sequence as the target arrangement sequence;

[0063] If the treatment success index is greater than or equal to the second treatment threshold and less than the first treatment threshold, then an equivalent medicine box is obtained using the spare medicine box, the equivalent medicine box is used as the target medicine box, and the drug arrangement sequence is used as the target arrangement sequence.

[0064] If the treatment success index is less than or equal to the second treatment threshold, the adverse reaction set, the updated basic indicator set, and the updated diagnostic indicators are integrated into an arrangement data package. The arrangement data package is sent to the pre-built doctor-patient analysis system to obtain the doctor-patient diagnostic system. Based on the doctor-patient diagnostic system and the available medicine boxes, the updated arrangement sequence and the updated medicine box are obtained. The updated medicine box is used as the target medicine box, and the updated arrangement sequence is used as the target arrangement sequence.

[0065] To achieve the above objectives, the present invention also provides a comprehensive drug treatment management system for patients with chronic kidney disease, comprising:

[0066] The patient data acquisition module is used to obtain the patient ID and read the kidney disease patient dataset from the pre-built hospital database based on the patient ID. The kidney disease patient dataset includes: patient age, patient weight, patient address, basic physical indicators, diagnostic physical indicators and medication schedule sequence. The time of reading the kidney disease patient dataset is used as the starting point and the time is recorded in real time to obtain the drug treatment time.

[0067] The smart pillbox monitoring module is used to send pre-built smart medical pillboxes to the patient's address. When the smart medical pillbox is signed for, an operational pillbox is obtained. The operational pillbox includes multiple ordinary pill compartments, and each ordinary pill compartment includes a pill compartment indicator light, a pill compartment number, and a pill compartment window. The medication administration sequence and the operational pillbox are used to obtain medication adherence and billing pillboxes. The billing pillboxes are then recycled to obtain empty pillboxes.

[0068] The success index calculation module is used to retrieve the adverse reaction set, update the basic indicator set, and update the diagnostic indicators from the pre-built patient management database based on the patient ID. The adverse reaction set includes n adverse reaction groups, and each adverse reaction group includes an adverse reaction number and an adverse reaction time. The module calculates drug inappropriateness using the patient's age, weight, adverse reaction set, and patient management database. It calculates the recovery rate and updates the average indicators using basic physical indicators, diagnostic physical indicators, updated basic indicator set, and updated diagnostic indicators. The module calculates the treatment success index based on medication adherence, drug inappropriateness, and recovery rate. Based on the available medicine boxes and the treatment success index, the module identifies the target medicine box and the target arrangement sequence.

[0069] The medication management cycle module is used to use the target pillbox as a medical smart pillbox, the target arrangement sequence as a medication arrangement sequence, the updated average index as a basic physical index, and the updated diagnostic index as a diagnostic physical index. It then returns to the step of sending the pre-built medical smart pillbox to the patient's address until the medication treatment time is greater than the preset total treatment time, thus completing the full-course medication treatment management for patients with chronic kidney disease.

[0070] To address the above problems, the present invention also provides an electronic device, the electronic device comprising:

[0071] Memory, storing at least one instruction;

[0072] The processor executes the instructions stored in the memory to implement the above-described method for comprehensive drug treatment management of patients with chronic kidney disease.

[0073] To address the aforementioned problems, the present invention also provides a computer-readable storage medium storing at least one instruction, which is executed by a processor in an electronic device to implement the aforementioned method for comprehensive drug treatment management for patients with chronic kidney disease.

[0074] To address the problems described in the background section, this invention obtains a patient ID and, based on this ID, retrieves a kidney disease patient dataset from a pre-built hospital database. This dataset includes patient age, weight, address, basic physical indicators, diagnostic physical indicators, and medication schedule sequences. The time of retrieving the kidney disease patient dataset is used as the starting point, and the time is recorded in real-time to obtain the medication treatment schedule. Therefore, this invention comprehensively covers various physical indicators of chronic kidney disease patients by retrieving the kidney disease patient dataset, providing data support for subsequent full-course medication management, improving the accuracy and efficiency of full-course medication management, and then delivering a pre-built smart medical pillbox to the patient's address. When the medication box is signed for, an operational medication box is obtained. This operational medication box includes multiple ordinary medication compartments, each compartment featuring a compartment indicator light, a compartment number, and a compartment window. Medication adherence and settlement medication boxes are obtained using the medication arrangement sequence and the operational medication box. A recycling operation is performed on the settlement medication boxes, resulting in empty medication boxes. This embodiment of the invention uses a medical smart medication box to promptly remind patients with chronic kidney disease to take their medication and monitors their medication adherence in real time, thereby calculating medication adherence. This facilitates subsequent calculation of the treatment success index based on medication adherence, ultimately identifying the target medication box and target arrangement sequence more suitable for patients with chronic kidney disease. This improves the accuracy and automation of the entire drug treatment management process. Based on the patient ID, a pre-built patient management system is used... The adverse reaction set, updated basic indicator set, and updated diagnostic indicators are retrieved from the database. The adverse reaction set includes n adverse reaction groups, each containing an adverse reaction number and time. Drug inappropriateness is calculated using patient age, patient weight, the adverse reaction set, and the patient management database. This embodiment of the invention calculates drug inappropriateness by retrieving the adverse reaction set of a chronic kidney disease patient during medication, allowing for timely adjustments to the target medication box based on drug inappropriateness, thus improving the accuracy of the entire drug treatment management process. The state recovery degree and updated average indicators are calculated using basic physical indicators, diagnostic physical indicators, the updated basic indicator set, and the updated diagnostic indicators. This embodiment of the invention reflects the state recovery degree... This invention reflects the improvement of chronic kidney disease patients' conditions, making subsequent adjustments to the target pillbox more precise. A treatment success index is calculated based on medication adherence, medication inappropriateness, and recovery status. The target pillbox and target arrangement sequence are identified based on available pillboxes and the treatment success index. Therefore, this embodiment of the invention calculates the treatment success index by considering medication adherence, medication inappropriateness, and recovery status, comprehensively reflecting the treatment effect on chronic kidney disease patients throughout the entire course of drug therapy management. The target pillbox is then identified based on the treatment effect, further improving the accuracy of the entire course of drug therapy management. The target pillbox serves as a medical intelligent pillbox, the target arrangement sequence serves as a drug arrangement sequence, and the updated average index serves as a basic physical indicator.The updated diagnostic indicators are used as diagnostic physical indicators. The process then returns to the step of sending the pre-built medical smart pillbox to the patient's address, continuing until the medication treatment time exceeds the preset total treatment time, thus completing the full-course medication management for patients with chronic kidney disease. It can be seen that this embodiment of the invention achieves a cyclical treatment process by using the target pillbox as the medical smart pillbox and returning to the step of sending the pre-built medical smart pillbox to the patient's address. This allows for real-time adjustment of the target pillbox based on the patient's physical condition and treatment effect during the cycle, improving the accuracy and automation of full-course medication management. Therefore, this invention can improve the accuracy and automation of full-course medication management and reduce the burden on hospital human resources. Attached Figure Description

[0075] Figure 1 This is a flowchart illustrating a method for managing the entire course of drug therapy for patients with chronic kidney disease, provided in an embodiment of the present invention.

[0076] Figure 2 This is a schematic diagram of a smart pillbox based on a comprehensive drug treatment management system for patients with chronic kidney disease, provided in an embodiment of the present invention.

[0077] Figure 3 This is a functional module diagram of a comprehensive drug treatment management system for patients with chronic kidney disease provided in an embodiment of the present invention;

[0078] Figure 4 This is a schematic diagram of the structure of an electronic device for implementing the method of full-process drug treatment management for patients with chronic kidney disease, according to an embodiment of the present invention.

[0079] Explanation of reference numerals in the attached figures:

[0080] 10. Electronic device; 11. Processor; 12. Memory; 13. Bus.

[0081] The realization of the objective, functional features and advantages of the present invention will be further explained in conjunction with the embodiments and with reference to the accompanying drawings. Detailed Implementation

[0082] It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.

[0083] This application provides a method for comprehensive drug treatment management for patients with chronic kidney disease. The executing entity of this method includes, but is not limited to, at least one electronic device that can be configured to execute the method provided in this application, such as a server or a terminal. In other words, the method for comprehensive drug treatment management for patients with chronic kidney disease can be executed by software or hardware installed on a terminal device or a server device, and the software may be a blockchain platform. The server includes, but is not limited to, a single server, a server cluster, a cloud server, or a cloud server cluster.

[0084] Reference Figure 1 The diagram shown is a flowchart illustrating a method for managing the entire course of drug therapy for patients with chronic kidney disease according to an embodiment of the present invention. In this embodiment, the method for managing the entire course of drug therapy for patients with chronic kidney disease includes:

[0085] S1. Obtain the patient ID. Based on the patient ID, read the kidney disease patient dataset from the pre-built hospital database. The kidney disease patient dataset includes: patient age, patient weight, patient address, basic physical indicators, diagnostic physical indicators, and medication schedule. Starting from the time when the kidney disease patient dataset is read, record the time in real time to obtain the medication treatment time.

[0086] In this embodiment of the invention, before implementing full-course drug treatment management for patients with chronic kidney disease (CKD), the hospital generates a unique number in its database to identify each CKD patient. This number is the patient ID, and each patient ID is unique, corresponding to a specific CKD patient. The hospital database stores datasets of CKD patients. When querying the dataset of a specific CKD patient, the dataset can be retrieved from the hospital database using the patient ID.

[0087] It should be explained that patient age, patient weight, and patient address refer to the age, weight, and home address of the patient with chronic kidney disease, respectively. These patient age, weight, and address are registered in advance by the patient and stored in the hospital database. Basic physical indicators include: basic heart rate, basic blood glucose, and basic blood pressure. Diagnostic physical indicators include: serum creatinine level and parathyroid hormone level. These basic heart rate, basic blood glucose, basic blood pressure, serum creatinine level, and parathyroid hormone level are all obtained during the initial physical examination of the patient with chronic kidney disease and stored in the hospital database. Basic heart rate, basic blood glucose, and basic blood pressure refer to the patient's heart rate, blood glucose, and blood pressure, respectively. Serum creatinine and parathyroid hormone levels refer to the concentrations of serum creatinine and parathyroid hormone in the blood of patients with chronic kidney disease (CKD), respectively. These levels can be obtained through routine blood tests. For example, after collecting venous blood from a CKD patient, the doctor divides the blood into two samples. One sample is placed in a biochemical analyzer, and the serum creatinine concentration is measured to be 70 μmol / L (i.e., serum creatinine level). The other sample is placed in a chemiluminescence immunoassay analyzer, and the parathyroid hormone concentration is measured to be 5 pmol / L (i.e., parathyroid hormone level). Both serum creatinine and parathyroid hormone levels are indicators reflecting kidney function in CKD patients. The medication schedule includes multiple medication data points, including medication reminder times and pharmacy inventory numbers.

[0088] For example, after a preliminary examination of a patient with chronic kidney disease, a doctor prescribes the following medication: Dapagliflozin 10 mg / day, taken at 8:00 PM daily, from day 1 to day 10; Alfacalcidol capsule one capsule / day, taken at 10:00 AM daily, from day 11 to day 20. The nurse then retrieves the medication according to the doctor's prescription, placing 10 mg of dapagliflozin in each of the first to tenth compartments of the smart pillbox, and one Alfacalcidol capsule in each of the eleventh to twentieth compartments, thus creating the smart pillbox. The nurse then inputs the medication count into a pre-built medical platform based on the compartment number and the prescribed dosage for each medication. For example, if the first medicine box has the medicine box number 1, and the medication in the first medicine box is to be taken at 20:00:00 daily, then the medicine box number is 1, the medication reminder time is 20:00:00, and the medication data entered by the nurse is (1, 20:00:00). After the nurse has entered the medication data for all 20 medicine boxes, the medical platform will sort the medication data according to the medicine box numbers in ascending order, obtaining the medication arrangement sequence: {(1, 20:00:00)…(10, 20:00:00),(11, 10:00:00)…(20, 10:00:00)}, and store the medication arrangement sequence in the hospital database. The medical system is a pre-programmed software platform using Python, and the technology of pre-programming the medical system with Python is existing technology and will not be elaborated here. For specific applications of the smart pillbox, please refer to the following embodiments.

[0089] For example, if the data set of kidney disease patients is read at 10:00 on October 1, then the time is recorded in real time starting from 10:00 on October 1. When the drug treatment time is 24 hours at 10:00 on October 2, and when the drug treatment time is 50 hours at 12:00 on October 3, the drug treatment time is 50 hours.

[0090] S2. The pre-built smart medical pillbox is sent to the patient's address. When the smart medical pillbox is signed for, an operational pillbox is obtained. The operational pillbox includes multiple ordinary pill compartments, and each ordinary pill compartment includes a pill compartment indicator light, a pill compartment number, and a pill compartment window.

[0091] It should be explained that a smart pillbox is a remotely controllable intelligent device with medication storage and management as its core functions. Its main purpose is to remind patients with chronic kidney disease to take their medication on time. The smart pillbox contains multiple compartments, which are the cells used to store medications. Optionally, the Fabián Vadillo smart pillbox can be used as the primary smart pillbox. Figure 2This is a schematic diagram of a smart pillbox. The pill compartment includes a pillbox indicator light, a pillbox number, and a pillbox window. The pillbox indicator light is an LED that flashes under remote control. Each pillbox in the smart pillbox has a corresponding pillbox number, which identifies its position within the box. For example, the pillbox number for the first pillbox in the lower left corner is 1, and the pillbox adjacent to and to the right of the first pillbox in the lower left corner is numbered 2. The pillbox window is a glass or plastic cover on the surface of the pillbox that can be opened or closed. It serves as the entrance for putting in medication and the exit for taking out medication. Opening the window allows medication to be put into or taken out of the pillbox, while closing the window ensures proper storage of the medication. A regular pillbox refers to the pillbox after medication has been placed inside; a medical smart pillbox refers to the smart pillbox after medication has been placed inside.

[0092] For example, after a nurse places multiple medications into multiple compartments of a smart pillbox according to a doctor's prescription, she obtains the smart pillbox and sends it to the patient's address via express delivery or personal delivery. When the patient signs for the smart pillbox, the signed smart pillbox is used as the operating pillbox.

[0093] S3. Use the drug arrangement sequence and operation of the pillbox to obtain medication compliance and settlement pillbox, and perform a recycling operation on the settlement pillbox to obtain empty pillboxes.

[0094] For example, after receiving the settlement medicine box, the hospital can pick it up by sending a pickup service and remove the remaining medicine from it, leaving an empty medicine box.

[0095] Specifically, the method of obtaining medication adherence and settling accounts using drug delivery sequences and pillboxes includes:

[0096] The system acquires the daily time in real time. When the daily time equals the preset start time, it extracts the first drug data from the drug arrangement sequence and marks the drug arrangement sequence after extracting the first drug data as a waiting arrangement sequence. The drug arrangement sequence includes multiple drug data, and the number of drug data in the drug arrangement sequence is equal to the number of ordinary drug compartments in the operating drug box. The drug data includes the drug reminder time and drug compartment number. The first drug data is the drug data that is ranked first in the drug arrangement sequence.

[0097] When the time of a single day is equal to the drug reminder time in the first drug data, ordinary drug warehouses with the same drug warehouse number as the drug warehouse number in the first drug data are marked as candidate drug warehouses;

[0098] Make the indicator light of the medicine warehouse in the candidate medicine warehouse flash, and obtain the flashing medicine warehouse. The time when the flashing medicine warehouse is obtained is taken as the starting point and the time is recorded in real time to obtain the flashing time.

[0099] The usage status of the medicine storage window corresponding to the flashing medicine storage is monitored in real time. The usage status includes: open state and closed state, and the initial state of the medicine storage window is closed.

[0100] When the medicine storage window is opened, the medicine storage indicator light of the flashing medicine storage stops flashing, indicating a successful medicine storage. The medication time is confirmed based on the flashing time, where the medication time is equal to the flashing time.

[0101] The medication time is recorded in a pre-constructed recording unit to obtain a statistical unit. It is then determined whether there is medication data in the waiting arrangement sequence. If there is medication data in the waiting arrangement sequence, the waiting arrangement sequence is used as the medication arrangement sequence, the statistical unit is used as the recording unit, and the process returns to the step of obtaining the daily time in real time.

[0102] When the flashing time reaches the preset reminder time threshold and the medicine warehouse window is closed, the medicine warehouse indicator light of the flashing medicine warehouse stops flashing, the failed medicine warehouse is obtained, and it is determined whether there is drug data in the waiting arrangement sequence. If there is drug data in the waiting arrangement sequence, the waiting arrangement sequence is used as the drug arrangement sequence, and the process returns to the step of real-time acquisition of daily time.

[0103] Until no drug data is found in the waiting arrangement sequence, the successful drug warehouses are aggregated to obtain multiple successful drug warehouses, and the failed drug warehouses are aggregated to obtain multiple failed drug warehouses. The number of multiple successful drug warehouses and the number of multiple failed drug warehouses are counted respectively to obtain the number of successes and the number of failures. Based on the multiple successful drug warehouses and the multiple failed drug warehouses, the settlement drug box is confirmed.

[0104] Multiple medication times are read from the statistical unit, and medication adherence is calculated based on the number of successful doses, the number of failed doses, and the multiple medication times.

[0105] It should be explained that "single-day time" refers to Beijing time, which excludes the year, month, and day, retaining only the hour, minute, and second. Optionally, the start time can be set to 00:00:00.

[0106] For example, if the current Beijing time is 23:00:00 on December 1, 2024, then the time of the day is 23:00:00. The time of the day is obtained in real time. If the preset start time is 00:00:00, when the time of the day reaches 00:00:00, the first drug data is extracted from the drug arrangement sequence.

[0107] It should be understood that since the nurse enters medication data based on the medication number of a pharmacy and the administration time of the medication in the pharmacy, while a regular pharmacy is a pharmacy after the medication has been placed inside, the number of medication data is equal to the number of regular pharmacy pharmacies.

[0108] For example, if the drug placement sequence is {(1, 20:00:00), (2, 20:00:00)…(10, 20:00:00), (11, 10:00:00)…(20, 10:00:00)}, then the first drug data is (1, 20:00:00), and the waiting placement sequence is {(2, 20:00:00)…(10, 20:00:00), (11, 10:00:00)…(20, 10:00:00)}. Since the drug storage unit number is 1 in the first drug data, the ordinary drug storage unit with drug storage unit number 1 is marked as a candidate drug storage unit. When the time of day is 20:00:00, the indicator light in the candidate drug storage unit starts flashing, thus creating a flashing drug storage unit. The time is recorded in real time starting from 20:00:00. At 20:00:01, the flashing time is 1 second; at 20:00:02, the flashing time is 2 seconds. The corresponding flashing drug storage unit is monitored in real time. The usage status of the medicine storage window is monitored. When the medicine storage window is detected to be open, the medicine storage indicator light stops flashing, indicating a successful medicine storage. If the time is 20:01:00, the flashing time is 60 seconds. This flashing time is taken as the medication time, which is 60 seconds. Since there is drug data in the waiting arrangement sequence, the waiting arrangement sequence is used as the drug arrangement sequence. The statistics unit is used as the recording unit, and the process returns to the step of obtaining the daily time in real time. If the start time is 00:00:00, when the daily time reaches 00:00:00, the first drug data is extracted from the drug arrangement sequence again, and the medication time is obtained again. This process is repeated, and the medication time obtained in each cycle is recorded in the recording unit until all drug data in the arrangement sequence has been extracted, i.e., when there is no drug data in the waiting arrangement sequence, the multiple medication times recorded by the statistics unit during the cycle are read.

[0109] It should be explained that the recording unit is a memory within the smart pillbox used to store medication administration times. Optionally, the reminder time threshold can be set to 180 seconds. The phrase "confirming the settlement pillbox based on multiple successful and multiple failed pillboxes" means that once all ordinary pillboxes in the operating pillbox have been confirmed as either successful or failed, the operating pillbox at that moment is used as the settlement pillbox.

[0110] In detail, the formula for calculating medication adherence is as follows:

[0111]

[0112] Where, τ CKD Medication adherence is represented by α (number of successful cases), β (number of failed cases), and t (number of expiratory cases). i For the i-th medication time among multiple medication times, t max The reminder time threshold is given, and ln is the natural logarithm.

[0113] It should be understood that medication adherence refers to the adherence of patients with chronic kidney disease to medication throughout the entire course of drug treatment management. It reflects the degree to which patients with chronic kidney disease follow the drug treatment plan provided by their doctors. The higher the medication adherence, the higher the degree to which patients with chronic kidney disease follow the drug treatment plan provided by their doctors.

[0114] S4. Based on the patient ID, retrieve the adverse reaction set, update the basic indicator set, and update the diagnostic indicators from the pre-built patient management database. The adverse reaction set includes n adverse reaction groups, and each adverse reaction group includes an adverse reaction number and an adverse reaction time.

[0115] It should be explained that the patient management database is used to record the adverse reaction set, update the basic indicator set, and update the diagnostic indicator of a patient throughout the entire drug treatment management process. When recording the adverse reaction set, update the basic indicator set, and update the diagnostic indicator of a patient, the patient management database will store the patient's patient ID, patient age, and patient weight in a folder for easy retrieval or query later.

[0116] It should be understood that patients with chronic kidney disease may experience some adverse reactions during the entire course of drug treatment and management. When a patient with chronic kidney disease notices an adverse reaction, they can select the corresponding adverse reaction number on a medical communication app on their mobile phone and submit the duration of the adverse reaction. The medical communication app will then upload and save the information in the patient management database. The medical communication app is a pre-programmed Java mobile app, and the technology of pre-programming the medical communication app in Java is existing technology and will not be elaborated here.

[0117] For example, a patient with chronic kidney disease experiences dizziness as an adverse reaction that lasts for 50 minutes. They then open a medical communication app, search for the keyword "dizziness" on the app, find the adverse reaction number 22, and submit the adverse reaction group (22, 50 minutes) in the feedback interface of the medical communication app. Here, 22 is the adverse reaction number, 50 minutes is the adverse reaction duration, and the adverse reaction duration is in minutes.

[0118] It is understood that the updated basic indicator set includes multiple updated indicators, including updated heart rate, updated blood glucose, and updated blood pressure. The updated heart rate, updated blood glucose, and updated blood pressure are monitored and uploaded to the patient management database by the patient using a smartwatch, a smart blood glucose analyzer, and a smart blood pressure monitor, respectively, throughout the entire drug treatment management process. The technology of using a smartwatch, a smart blood glucose analyzer, and a smart blood pressure monitor to monitor and update heart rate, updated blood glucose, and updated blood pressure and upload them to the patient management database is existing technology and will not be elaborated here.

[0119] It should be understood that patients with chronic kidney disease will have regular follow-up visits to the hospital during the entire course of drug treatment and management. Therefore, the indicators recorded in the patient management database at the most recent follow-up visit will be used as updated diagnostic indicators. The updated diagnostic indicators include: updated serum creatinine level and updated parathyroid hormone level. Updated serum creatinine level and updated parathyroid hormone level refer to the serum creatinine level and parathyroid hormone level detected in patients with chronic kidney disease at the follow-up visit, respectively.

[0120] S5. Calculate drug inappropriateness using patient age, patient weight, adverse reaction set, and patient management database.

[0121] Specifically, the calculation of drug inappropriateness using patient age, patient weight, adverse reaction set, and patient management database includes:

[0122] Obtain the adverse reaction sequence, wherein the adverse reaction sequence includes m adverse reaction numbers;

[0123] For each adverse reaction group in the adverse reaction set, the following procedures were performed:

[0124] Adverse reaction numbers that are identical to adverse reaction numbers in the adverse reaction sequence are identified as pending confirmation numbers, and the position of the pending confirmation number in the adverse reaction sequence is used as the adverse reaction position.

[0125] The adverse reaction coefficient is calculated based on the adverse reaction ranking and the adverse reaction time in the adverse reaction group, using the following formula:

[0126]

[0127] Where, p f Here, x represents the adverse reaction coefficient, and t represents the adverse reaction ranking. f This refers to the time of adverse reaction.

[0128] Summarize the adverse reaction coefficients to obtain n adverse reaction coefficients, and calculate the adverse reaction index based on the n adverse reaction coefficients, where the adverse reaction index is the sum of the n adverse reaction coefficients;

[0129] Based on the patient's age, an age range is determined. Based on the age range, N reference patient information is retrieved from the patient management database. The reference patient information includes: reference response set, reference weight, and reference age, and the reference age is within the age range.

[0130] For each of the N reference patient records, perform the following operation:

[0131] The reference response index is obtained based on the reference response set in the reference patient information.

[0132] By summing the reference response indices, N reference response indices are obtained;

[0133] Drug inappropriateness is calculated based on the adverse reaction index, N reference reaction indices, patient age, and patient weight.

[0134] It should be understood that the adverse reaction sequence is pre-constructed by the doctor based on the severity of the adverse reactions, and the adverse reaction sequence includes: m adverse reaction numbers, each of which refers to an adverse reaction. For example, when the adverse reaction number is 22, it refers to the adverse reaction of dizziness. The m adverse reaction numbers are sorted from mild to severe according to the severity of their corresponding adverse reactions. It should be noted that the specific adverse reaction that each adverse reaction number refers to is determined by the doctor, and the order of the severity of the adverse reactions is set in advance by the doctor based on medical experience.

[0135] For example, there are 50 adverse reaction numbers, with adverse reaction number 22 and adverse reaction duration of 30 minutes. Therefore, adverse reaction number 22 is found to be the 10th position in the adverse reaction sequence, and the adverse reaction coefficient is calculated as follows:

[0136] It should be explained that the adverse reaction coefficient reflects the severity of a single adverse reaction in a patient with chronic kidney disease (CKD). The higher the adverse reaction coefficient, the more severe the single adverse reaction in a CKD patient. The adverse reaction index reflects the overall severity of multiple adverse reactions in a CKD patient. The higher the adverse reaction index, the more severe the overall severity of multiple adverse reactions in a CKD patient.

[0137] It should be understood that the patient management database records adverse reactions of multiple chronic kidney disease patients throughout their entire course of drug treatment management. Therefore, this embodiment of the invention retrieves N reference patient information from the patient management database based on age range, thereby providing a reference for the currently treated chronic kidney disease patients. For example, a certain mild adverse reaction may occur in most chronic kidney disease patients during treatment. Therefore, after calculation, the N reference reaction indices may all be around the same value (assuming it is 20). If the calculated adverse reaction index is 50, it reflects that the adverse reaction experienced by the patient corresponding to the adverse reaction index is abnormal, and the calculated drug intolerance is too high, reflecting that the patient's adaptability to the drug is lower than that of other patients during the entire course of drug treatment management. Therefore, the subsequent calculated treatment success index will also be lower, requiring the doctor to pay close attention.

[0138] It should be explained that the reference response set, reference weight, and reference age refer to the adverse reaction sets, weights, and ages of other chronic kidney disease patients used for reference in the patient management database, respectively. The method for obtaining the reference response index based on the reference response set in the reference patient information is the same as the method for obtaining the adverse reaction index using the adverse reaction set, and will not be repeated here.

[0139] Specifically, the determination of the age range based on the patient's age includes:

[0140] The maximum and minimum ages are calculated based on the patient's age and a preset similar age. The maximum age is the sum of the patient's age and the similar age, and the minimum age is the absolute difference between the patient's age and the similar age.

[0141] An age range is determined based on the maximum and minimum ages, where the maximum age is the maximum age and the minimum age is the minimum age.

[0142] Optionally, the similar age can be set to 5 years.

[0143] Specifically, the calculation of drug inappropriateness based on the adverse reaction index, N reference reaction indices, patient age, and patient weight includes:

[0144] The target reference index is calculated based on N reference response indices, the patient's age, and the patient's weight, using the following formula:

[0145]

[0146] Where, μ x The target reference index is Y0, where Y0 is the patient's age, G0 is the patient's weight, and P is the target reference index. i Y is the i-th reference response index among N reference response indices. i and Gi These are the reference age and reference weight corresponding to the i-th reference response index among N reference response indices, where | represents taking the absolute value;

[0147] Drug inappropriateness is calculated based on the adverse reaction index and the target reference index, using the following formula:

[0148]

[0149] Where, μ CKD For inappropriate medication, μ x This is the adverse reaction index.

[0150] It should be understood that when calculating the target reference index, the age and weight similarity between the current chronic kidney disease (CKD) patient and other CKD patients are considered. The higher the age and weight similarity corresponding to the reference response index, the higher the weight of the reference response index in the calculation of the target reference index. Therefore, the target reference index reflects the severity of adverse reactions experienced by multiple CKD patients similar to the current CKD patient during the entire course of drug treatment management. The larger the target reference index, the higher the severity of adverse reactions experienced by multiple CKD patients similar to the current CKD patient during the entire course of drug treatment management. Drug inadequacy reflects the drug tolerance of the current CKD patient compared to other CKD patients during the entire course of drug treatment management. The higher the drug inadequacy, the lower the drug tolerance of the current CKD patient compared to other CKD patients during the entire course of drug treatment management.

[0151] S6. Calculate the state recovery degree and update the average index using basic physical indicators, diagnostic physical indicators, updated basic indicator set and updated diagnostic indicators.

[0152] In detail, the calculation of state recovery degree and the update of average index using basic physical indicators, diagnostic physical indicators, updated basic indicator set, and updated diagnostic indicators includes:

[0153] The updated mean heart rate, updated mean blood glucose, and updated mean blood pressure are calculated based on the updated basic indicator set. The updated basic indicator set includes multiple updated indicators, and the updated indicators include updated heart rate, updated blood glucose, and updated blood pressure. The updated mean heart rate, updated mean blood glucose, and updated mean blood pressure are the average values ​​of the updated heart rate, updated blood glucose, and updated blood pressure corresponding to the multiple updated indicators, respectively.

[0154] The updated average indicators are obtained by summarizing and updating the average heart rate, average blood glucose, and average blood pressure.

[0155] Recovery status is calculated based on basic physical indicators, diagnostic physical indicators, updated average indicators, and updated diagnostic indicators. Basic physical indicators include: basic heart rate, basic blood glucose, and basic blood pressure. Diagnostic physical indicators include: serum creatinine level and parathyroid hormone level. Updated diagnostic indicators include: updated serum creatinine level and updated parathyroid hormone level. The formula for calculating recovery status is shown below:

[0156]

[0157] Where, θ CKD To indicate recovery status, HR0, BG0, and BP0 represent baseline heart rate, baseline blood glucose, and baseline blood pressure, respectively. and These represent the updated mean heart rate, updated mean blood glucose, and updated mean blood pressure, respectively, among the updated mean indicators. Cr0 and PTH0 represent serum creatinine and parathyroid hormone levels, respectively. x and PTH x These are the refreshed serum creatinine level and the refreshed parathyroid hormone level, respectively, HR best The preset optimal heart rate is defined as a0, the preset serum creatinine weight is b0, and the preset parathyroid hormone weight is b0.

[0158] It should be explained that the optimal heart rate, serum creatinine weight, and parathyroid hormone weight are all set by doctors based on existing medical literature or medical experience.

[0159] It should be understood that the recovery rate reflects the degree of improvement in the condition of patients with chronic kidney disease; the higher the recovery rate, the greater the improvement in the condition of patients with chronic kidney disease.

[0160] In detail, the formula for calculating the treatment success index is as follows:

[0161]

[0162] Among them, Tr CKD The success rate index is denoted by e, which is a natural constant.

[0163] It should be understood that the treatment success index is a value that comprehensively evaluates the treatment effect of full-course drug therapy management on patients with chronic kidney disease. The higher the treatment success index, the better the treatment effect of full-course drug therapy management on patients with chronic kidney disease.

[0164] S7. Calculate the treatment success index based on medication adherence, medication inappropriateness, and recovery status. Identify the target pillbox and target arrangement sequence based on available pillboxes and the treatment success index.

[0165] Specifically, the identification of the target pillbox and target arrangement sequence based on available pillboxes and treatment success index includes:

[0166] The treatment success index is compared with a preset first treatment threshold and the treatment success index is compared with a preset second treatment threshold, wherein the first treatment threshold is greater than the second treatment threshold;

[0167] If the treatment success index is greater than or equal to the first treatment threshold, then obtain the health care arrangement sequence, and use the empty medicine box to obtain the health care medicine box, use the health care medicine box as the target medicine box, and use the health care arrangement sequence as the target arrangement sequence;

[0168] If the treatment success index is greater than or equal to the second treatment threshold and less than the first treatment threshold, then an equivalent medicine box is obtained using the spare medicine box, the equivalent medicine box is used as the target medicine box, and the drug arrangement sequence is used as the target arrangement sequence.

[0169] If the treatment success index is less than or equal to the second treatment threshold, the adverse reaction set, the updated basic indicator set, and the updated diagnostic indicators are integrated into an arrangement data package. The arrangement data package is sent to the pre-built doctor-patient analysis system to obtain the doctor-patient diagnostic system. Based on the doctor-patient diagnostic system and the available medicine boxes, the updated arrangement sequence and the updated medicine box are obtained. The updated medicine box is used as the target medicine box, and the updated arrangement sequence is used as the target arrangement sequence.

[0170] It should be explained that both the first and second treatment thresholds are set by doctors based on historical treatment experience. For example, if a patient with chronic kidney disease is diagnosed by a doctor as having basically recovered and no longer needs to take medication for chronic kidney disease, but only needs to take nutritional supplements, then the doctor can use the average treatment success rate of multiple patients with chronic kidney disease who have been diagnosed by the doctor and have basically recovered as the first treatment threshold. Similarly, the doctor can use the average treatment success rate of multiple patients with chronic kidney disease who have been diagnosed by the doctor and whose condition has significantly worsened as the second treatment threshold.

[0171] It should be understood that since the main function of health care products is to supplement the body's nutrition and has little relation to the patient's physical condition, the types, quantities, and arrangements of health care products in each compartment of the health care medicine box are preset and fixed by the doctor based on medical experience and will not change due to different patients. Similarly, the health care arrangement sequence generated by the nurse in the medical platform is also fixed.

[0172] For example, when the treatment success index is greater than or equal to the first treatment threshold, the nurse takes the following medication according to the doctor's pre-provided prescription: from day 1 to day 10, take one vitamin tablet per day at 10:00:00; from day 11 to day 20, take one fish oil capsule per day at 10:00:00. The nurse then takes the medication according to the doctor's prescription, placing one vitamin tablet in each of the first to tenth compartments of the empty medicine box, and one fish oil capsule in each of the eleventh to twentieth compartments of the empty medicine box, thus obtaining the health care medicine box. The nurse then inputs the medication data into the medical platform based on the medication compartment number and the dosage time of each medication in the health care pillbox. For example, if the first medication compartment's compartment number is 1, and the dosage time for the first medication in the first compartment is 10:00:00 daily, then the compartment number is 1, and the dosage reminder time is 10:00:00. Therefore, the nurse inputs the health care medication data as (1, 10:00:00). After the nurse has inputted the medication data for all 20 compartments, the medical platform sorts the health care medication data in ascending order of compartment number to obtain a health care arrangement sequence. If the treatment success index is greater than or equal to the second treatment threshold but less than the first treatment threshold, the nurse, based on the prescription corresponding to the smart medical pillbox, refills the empty compartments with medications of the exact same quantity, type, and arrangement as those in the smart medical pillbox, resulting in an equivalent pillbox. If the treatment success index is less than or equal to the second treatment threshold, the adverse reaction set, the updated basic indicator set, and the updated diagnostic indicators are integrated into a scheduling data package. This scheduling data package is sent to the patient-doctor analysis system. The doctor, in the hospital analysis system, re-diagnoses the patient based on the adverse reaction set, the updated basic indicator set, and the updated diagnostic indicators, and prescribes an updated prescription. The nurse then uses the updated prescription and available pillboxes to obtain the updated scheduling sequence and updated pillboxes. The method for obtaining the updated scheduling sequence and updated pillboxes using the updated prescription and available pillboxes is the same as the method for obtaining the health care scheduling sequence and health care pillboxes using the health care prescription and available pillboxes.

[0173] It should be explained that the doctor-patient analysis system is a pre-built software platform using Python. It receives scheduling data packets, parses out the adverse reaction set, updated basic indicator set, and updated diagnostic indicator from the scheduling data packets, and displays them on the computer screen. This allows doctors to quickly prescribe updated medications for patients with chronic kidney disease based on the adverse reaction set, updated basic indicator set, and updated diagnostic indicator, thereby obtaining the updated scheduling sequence and updated medication kit.

[0174] S8. Using the target pillbox as the medical smart pillbox, the target arrangement sequence as the drug arrangement sequence, the updated average index as the basic physical index, and the updated diagnostic index as the diagnostic physical index, return to the step of sending the pre-constructed medical smart pillbox to the patient's address until the drug treatment time is greater than the preset total treatment time, thus completing the full-course drug treatment management for patients with chronic kidney disease.

[0175] It should be understood that each medical smart pillbox sent can only store about 20 days' worth of medication. However, the treatment course for patients with chronic kidney disease is very long, and the entire course of drug treatment management usually lasts for about a year. Therefore, it is necessary to send the medical smart pillbox multiple times and collect the pillbox for settlement.

[0176] It should be explained that the entire treatment time is set by the doctor based on the patient's physical condition and treatment wishes.

[0177] To address the problems described in the background section, this invention obtains a patient ID and, based on this ID, retrieves a kidney disease patient dataset from a pre-built hospital database. This dataset includes patient age, weight, address, basic physical indicators, diagnostic physical indicators, and medication schedule sequences. The time of retrieving the kidney disease patient dataset is used as the starting point, and the time is recorded in real-time to obtain the medication treatment schedule. Therefore, this invention comprehensively covers various physical indicators of chronic kidney disease patients by retrieving the kidney disease patient dataset, providing data support for subsequent full-course medication management, improving the accuracy and efficiency of full-course medication management, and then delivering a pre-built smart medical pillbox to the patient's address. When the medication box is signed for, an operational medication box is obtained. This operational medication box includes multiple ordinary medication compartments, each compartment featuring a compartment indicator light, a compartment number, and a compartment window. Medication adherence and settlement medication boxes are obtained using the medication arrangement sequence and the operational medication box. A recycling operation is performed on the settlement medication boxes, resulting in empty medication boxes. This embodiment of the invention uses a medical smart medication box to promptly remind patients with chronic kidney disease to take their medication and monitors their medication adherence in real time, thereby calculating medication adherence. This facilitates subsequent calculation of the treatment success index based on medication adherence, ultimately identifying the target medication box and target arrangement sequence more suitable for patients with chronic kidney disease. This improves the accuracy and automation of the entire drug treatment management process. Based on the patient ID, a pre-built patient management system is used... The adverse reaction set, updated basic indicator set, and updated diagnostic indicators are retrieved from the database. The adverse reaction set includes n adverse reaction groups, each containing an adverse reaction number and time. Drug inappropriateness is calculated using patient age, patient weight, the adverse reaction set, and the patient management database. This embodiment of the invention calculates drug inappropriateness by retrieving the adverse reaction set of a chronic kidney disease patient during medication, allowing for timely adjustments to the target medication box based on drug inappropriateness, thus improving the accuracy of the entire drug treatment management process. The state recovery degree and updated average indicators are calculated using basic physical indicators, diagnostic physical indicators, the updated basic indicator set, and the updated diagnostic indicators. This embodiment of the invention reflects the state recovery degree... This invention reflects the improvement of chronic kidney disease patients' conditions, making subsequent adjustments to the target pillbox more precise. A treatment success index is calculated based on medication adherence, medication inappropriateness, and recovery status. The target pillbox and target arrangement sequence are identified based on available pillboxes and the treatment success index. Therefore, this embodiment of the invention calculates the treatment success index by considering medication adherence, medication inappropriateness, and recovery status, comprehensively reflecting the treatment effect on chronic kidney disease patients throughout the entire course of drug therapy management. The target pillbox is then identified based on the treatment effect, further improving the accuracy of the entire course of drug therapy management. The target pillbox serves as a medical intelligent pillbox, the target arrangement sequence serves as a drug arrangement sequence, and the updated average index serves as a basic physical indicator.The updated diagnostic indicators are used as diagnostic physical indicators. The process then returns to the step of sending the pre-built medical smart pillbox to the patient's address, continuing until the medication treatment time exceeds the preset total treatment time, thus completing the full-course medication management for patients with chronic kidney disease. It can be seen that this embodiment of the invention achieves a cyclical treatment process by using the target pillbox as the medical smart pillbox and returning to the step of sending the pre-built medical smart pillbox to the patient's address. This allows for real-time adjustment of the target pillbox based on the patient's physical condition and treatment effect during the cycle, improving the accuracy and automation of full-course medication management. Therefore, this invention can improve the accuracy and automation of full-course medication management and reduce the burden on hospital human resources.

[0178] like Figure 3 The diagram shown is a functional block diagram of a comprehensive drug treatment management system for patients with chronic kidney disease provided in an embodiment of the present invention.

[0179] The comprehensive drug treatment management system 100 for patients with chronic kidney disease described in this invention can be installed in an electronic device. Depending on the functions implemented, the comprehensive drug treatment management system 100 for patients with chronic kidney disease may include a patient data acquisition module 101, a smart pillbox monitoring module 102, a success index calculation module 103, and a drug management cycle module 104. The module described in this invention can also be referred to as a unit, which refers to a series of computer program segments that can be executed by the processor of an electronic device and can perform a fixed function, and are stored in the memory of the electronic device.

[0180] The patient data acquisition module 101 is used to acquire the patient ID and read the kidney disease patient dataset from the pre-built hospital database based on the patient ID. The kidney disease patient dataset includes: patient age, patient weight, patient address, basic physical indicators, diagnostic physical indicators and medication schedule sequence. The time of reading the kidney disease patient dataset is taken as the starting point and the time is recorded in real time to obtain the drug treatment time.

[0181] The smart pillbox monitoring module 102 is used to send the pre-built medical smart pillbox to the patient's address. When the medical smart pillbox is signed for, an operational pillbox is obtained. The operational pillbox includes multiple ordinary pill compartments, and each ordinary pill compartment includes a pill compartment indicator light, a pill compartment number, and a pill compartment window. The medication arrangement sequence and the operational pillbox are used to obtain medication adherence and settlement pillboxes. A recycling operation is performed on the settlement pillboxes to obtain empty pillboxes.

[0182] The success index calculation module 103 is used to read the adverse reaction set, update the basic indicator set, and update the diagnostic indicator from the pre-built patient management database based on the patient ID. The adverse reaction set includes n adverse reaction groups, and each adverse reaction group includes an adverse reaction number and an adverse reaction time. The module calculates drug inappropriateness using the patient's age, weight, adverse reaction set, and patient management database. It calculates the state recovery degree and updates the average indicator using the basic physical indicators, diagnostic physical indicators, updated basic indicator set, and updated diagnostic indicator. The module calculates the treatment success index based on medication adherence, drug inappropriateness, and state recovery. The module identifies the target drug box and target arrangement sequence based on the available drug boxes and the treatment success index.

[0183] The drug management cycle module 104 is used to take the target pillbox as a medical smart pillbox, the target arrangement sequence as a drug arrangement sequence, the updated average index as a basic physical index, and the updated diagnostic index as a diagnostic physical index, and return to the step of sending the pre-built medical smart pillbox to the patient's address, until the drug treatment time is greater than the preset total treatment time, thus completing the full-course drug treatment management for patients with chronic kidney disease.

[0184] In detail, the modules in the comprehensive drug treatment management system 100 for patients with chronic kidney disease described in this embodiment of the invention employ the same methods as described above. Figure 1 The techniques used are the same as those described in the article regarding the comprehensive drug treatment management of patients with chronic kidney disease, and can produce the same technical effects, so they will not be elaborated here.

[0185] like Figure 4 The diagram shown is a schematic representation of an electronic device for implementing a comprehensive drug treatment management method for patients with chronic kidney disease, according to an embodiment of the present invention.

[0186] The electronic device 1 may include a processor 10, a memory 11 and a bus 12, and may also include a computer program stored in the memory 11 and executable on the processor 10, such as a program for managing the entire course of drug therapy for patients with chronic kidney disease.

[0187] The memory 11 includes at least one type of readable storage medium, such as flash memory, portable hard drive, multimedia card, card-type memory (e.g., SD or DX memory), magnetic memory, disk, optical disk, etc. In some embodiments, the memory 11 can be an internal storage unit of the electronic device 1, such as a portable hard drive. In other embodiments, the memory 11 can be an external storage device of the electronic device 1, such as a plug-in portable hard drive, smart media card (SMC), secure digital card (SD), flash card, etc., equipped on the electronic device 1. Furthermore, the memory 11 includes both internal and external storage units of the electronic device 1. The memory 11 can be used not only to store application software and various types of data installed on the electronic device 1, such as code for a program based on a comprehensive drug treatment management method for patients with chronic kidney disease, but also to temporarily store data that has been output or will be output.

[0188] In some embodiments, the processor 10 may be composed of integrated circuits, such as a single packaged integrated circuit or multiple integrated circuits with the same or different functions, including combinations of one or more central processing units (CPUs), microprocessors, digital processing chips, graphics processors, and various control chips. The processor 10 is the control unit of the electronic device, connecting various components of the entire electronic device through various interfaces and lines. It executes programs or modules stored in the memory 11 (e.g., a program for managing the entire course of drug treatment for patients with chronic kidney disease) and calls data stored in the memory 11 to perform various functions of the electronic device 1 and process data.

[0189] The bus 12 can be a peripheral component interconnect (PCI) bus or an extended industry standard architecture (EISA) bus, etc. The bus 12 can be divided into an address bus, a data bus, a control bus, etc. The bus 12 is configured to realize the connection and communication between the memory 11 and at least one processor 10, etc.

[0190] Figure 4 Only electronic devices with components are shown; those skilled in the art will understand that... Figure 4The structure shown does not constitute a limitation on the electronic device 1, and may include fewer or more components than shown, or combine certain components, or have different component arrangements.

[0191] For example, although not shown, the electronic device 1 may also include a power supply (such as a battery) to power various components. Preferably, the power supply can be logically connected to the at least one processor 10 through a power management device, thereby enabling functions such as charging management, discharging management, and power consumption management. The power supply may also include one or more DC or AC power supplies, recharging devices, power fault detection circuits, power converters or inverters, power status indicators, and other arbitrary components. The electronic device 1 may also include various sensors, Bluetooth modules, Wi-Fi modules, etc., which will not be described in detail here.

[0192] Furthermore, the electronic device 1 may also include a network interface. Optionally, the network interface may include a wired interface and / or a wireless interface (such as a Wi-Fi interface, a Bluetooth interface, etc.), which is typically used to establish communication connections between the electronic device 1 and other electronic devices.

[0193] Optionally, the electronic device 1 may further include a user interface, which may be a display, an input unit (such as a keyboard), or a standard wired or wireless interface. Optionally, in some embodiments, the display may be an LED display, a liquid crystal display, a touch-sensitive liquid crystal display, or an OLED (Organic Light-Emitting Diode) touchscreen. The display may also be appropriately referred to as a screen or display unit, used to display information processed in the electronic device 1 and to display a visual user interface.

[0194] The program for comprehensive drug treatment management for patients with chronic kidney disease, stored in the memory 11 of the electronic device 1, is a combination of multiple instructions. When run in the processor 10, it can achieve the following:

[0195] Obtain the patient ID, and read the kidney disease patient dataset from the pre-built hospital database based on the patient ID. The kidney disease patient dataset includes: patient age, patient weight, patient address, basic physical indicators, diagnostic physical indicators and medication schedule. Starting from the time when the kidney disease patient dataset is read, the time is recorded in real time to obtain the drug treatment time.

[0196] The pre-built smart medical pillbox is sent to the patient's address. When the smart medical pillbox is signed for, an operational pillbox is obtained. The operational pillbox includes multiple ordinary pill compartments, and each ordinary pill compartment includes a pill compartment indicator light, a pill compartment number, and a pill compartment window.

[0197] Medication adherence and billing pillboxes are obtained by using drug arrangement sequence and pillbox operation. The billing pillboxes are then recycled to obtain empty pillboxes.

[0198] Based on the patient ID, the adverse reaction set, the updated basic indicator set, and the updated diagnostic indicators are retrieved from the pre-built patient management database. The adverse reaction set includes n adverse reaction groups, and each adverse reaction group includes an adverse reaction number and an adverse reaction time.

[0199] Drug inappropriateness was calculated using patient age, patient weight, adverse reaction set, and patient management database.

[0200] The status recovery degree and updated average index are calculated using basic physical indicators, diagnostic physical indicators, updated basic indicator set and updated diagnostic indicators.

[0201] The treatment success index is calculated based on medication adherence, medication inappropriateness, and recovery status. The target pillbox and target arrangement sequence are then identified based on the available pillboxes and the treatment success index.

[0202] The target pillbox is used as a medical smart pillbox, the target arrangement sequence is used as a drug arrangement sequence, the updated average index is used as a basic physical index, and the updated diagnostic index is used as a diagnostic physical index. The process returns to the step of sending the pre-constructed medical smart pillbox to the patient's address until the drug treatment time is longer than the preset total treatment time, thus completing the full-course drug treatment management for patients with chronic kidney disease.

[0203] Specifically, the processor 10's implementation method for the above instructions can be found in [reference needed]. Figures 1 to 4 The descriptions of the relevant steps in the corresponding embodiments are not repeated here.

[0204] Furthermore, if the modules / units integrated in the electronic device 1 are implemented as software functional units and sold or used as independent products, they can be stored in a computer-readable storage medium. The computer-readable storage medium can be volatile or non-volatile. For example, the computer-readable medium may include: any entity or device capable of carrying the computer program code, a recording medium, a USB flash drive, a portable hard drive, a magnetic disk, an optical disk, a computer memory, or a read-only memory (ROM).

[0205] The present invention also provides a computer-readable storage medium storing a computer program, which, when executed by a processor of an electronic device, can perform the following:

[0206] Obtain the patient ID, and read the kidney disease patient dataset from the pre-built hospital database based on the patient ID. The kidney disease patient dataset includes: patient age, patient weight, patient address, basic physical indicators, diagnostic physical indicators and medication schedule. Starting from the time when the kidney disease patient dataset is read, the time is recorded in real time to obtain the drug treatment time.

[0207] The pre-built smart medical pillbox is sent to the patient's address. When the smart medical pillbox is signed for, an operational pillbox is obtained. The operational pillbox includes multiple ordinary pill compartments, and each ordinary pill compartment includes a pill compartment indicator light, a pill compartment number, and a pill compartment window.

[0208] Medication adherence and billing pillboxes are obtained by using drug arrangement sequence and pillbox operation. The billing pillboxes are then recycled to obtain empty pillboxes.

[0209] Based on the patient ID, the adverse reaction set, the updated basic indicator set, and the updated diagnostic indicators are retrieved from the pre-built patient management database. The adverse reaction set includes n adverse reaction groups, and each adverse reaction group includes an adverse reaction number and an adverse reaction time.

[0210] Drug inappropriateness was calculated using patient age, patient weight, adverse reaction set, and patient management database.

[0211] The status recovery degree and updated average index are calculated using basic physical indicators, diagnostic physical indicators, updated basic indicator set and updated diagnostic indicators.

[0212] The treatment success index is calculated based on medication adherence, medication inappropriateness, and recovery status. The target pillbox and target arrangement sequence are then identified based on the available pillboxes and the treatment success index.

[0213] The target pillbox is used as a medical smart pillbox, the target arrangement sequence is used as a drug arrangement sequence, the updated average index is used as a basic physical index, and the updated diagnostic index is used as a diagnostic physical index. The process returns to the step of sending the pre-constructed medical smart pillbox to the patient's address until the drug treatment time is longer than the preset total treatment time, thus completing the full-course drug treatment management for patients with chronic kidney disease.

[0214] In the embodiments provided by this invention, it should be understood that the disclosed devices, systems, and methods can be implemented in other ways. For example, the system embodiments described above are merely illustrative, and actual implementations may have other classification methods.

[0215] The modules described as separate components may or may not be physically separate. The components shown as modules may or may not be physical units; that is, they may be located in one place or distributed across multiple network units. Some or all of the modules can be selected to achieve the purpose of this embodiment according to actual needs.

[0216] Furthermore, the functional modules in the various embodiments of the present invention can be integrated into one processing unit, or each unit can exist physically separately, or two or more units can be integrated into one unit. The integrated unit can be implemented in hardware or in the form of hardware plus software functional modules.

[0217] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the present invention can be implemented in other specific forms without departing from the spirit or essential characteristics of the present invention.

[0218] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.

Claims

1. A method for managing the entire course of drug therapy for patients with chronic kidney disease, characterized in that, The method includes: Obtain the patient ID, and read the kidney disease patient dataset from the pre-built hospital database based on the patient ID. The kidney disease patient dataset includes: patient age, patient weight, patient address, basic physical indicators, diagnostic physical indicators and medication schedule. Starting from the time when the kidney disease patient dataset is read, the time is recorded in real time to obtain the drug treatment time. The pre-built smart medical pillbox is sent to the patient's address. When the smart medical pillbox is signed for, an operational pillbox is obtained. The operational pillbox includes multiple ordinary pill compartments, and each ordinary pill compartment includes a pill compartment indicator light, a pill compartment number, and a pill compartment window. Medication adherence and billing pillboxes are obtained by using drug arrangement sequences and pillbox operation. The billing pillboxes are then recycled to obtain empty pillboxes. Based on the patient ID, the adverse reaction set, the updated basic indicator set, and the updated diagnostic indicators are retrieved from the pre-built patient management database. The adverse reaction set includes n adverse reaction groups, and each adverse reaction group includes an adverse reaction number and an adverse reaction time. Drug inappropriateness was calculated using patient age, patient weight, adverse reaction set, and patient management database. The status recovery degree and the updated average index are calculated using basic physical indicators, diagnostic physical indicators, updated basic indicator set and updated diagnostic indicators. The treatment success index is calculated based on medication adherence, medication inappropriateness, and recovery status. The target pillbox and target arrangement sequence are then identified based on the available pillboxes and the treatment success index. The target pillbox is used as a medical smart pillbox, the target arrangement sequence is used as a drug arrangement sequence, the updated average index is used as a basic physical index, and the updated diagnostic index is used as a diagnostic physical index. The process returns to the step of sending the pre-constructed medical smart pillbox to the patient's address until the drug treatment time is longer than the preset total treatment time, thus completing the full-course drug treatment management for patients with chronic kidney disease.

2. The method for comprehensive drug treatment management of patients with chronic kidney disease as described in claim 1, characterized in that, The method of obtaining medication adherence and settling accounts using drug delivery sequences and pillbox operation includes: The system acquires the daily time in real time. When the daily time equals the preset start time, it extracts the first drug data from the drug arrangement sequence and marks the drug arrangement sequence after extracting the first drug data as a waiting arrangement sequence. The drug arrangement sequence includes multiple drug data, and the number of drug data in the drug arrangement sequence is equal to the number of ordinary drug compartments in the operating drug box. The drug data includes the drug reminder time and drug compartment number. The first drug data is the drug data that is ranked first in the drug arrangement sequence. When the time of a single day is equal to the drug reminder time in the first drug data, ordinary drug warehouses with the same drug warehouse number as the drug warehouse number in the first drug data are marked as candidate drug warehouses; Make the indicator light of the medicine warehouse in the candidate medicine warehouse flash, and obtain the flashing medicine warehouse. The time when the flashing medicine warehouse is obtained is taken as the starting point and the time is recorded in real time to obtain the flashing time. The usage status of the medicine storage window corresponding to the flashing medicine storage is monitored in real time. The usage status includes: open state and closed state, and the initial state of the medicine storage window is closed. When the medicine storage window is opened, the medicine storage indicator light of the flashing medicine storage stops flashing, indicating a successful medicine storage. The medication time is confirmed based on the flashing time, where the medication time is equal to the flashing time. The medication time is recorded in a pre-constructed recording unit to obtain a statistical unit. It is then determined whether there is medication data in the waiting arrangement sequence. If there is medication data in the waiting arrangement sequence, the waiting arrangement sequence is used as the medication arrangement sequence, the statistical unit is used as the recording unit, and the process returns to the step of obtaining the daily time in real time. When the flashing time reaches the preset reminder time threshold and the medicine warehouse window is closed, the medicine warehouse indicator light of the flashing medicine warehouse stops flashing, the failed medicine warehouse is obtained, and it is determined whether there is drug data in the waiting arrangement sequence. If there is drug data in the waiting arrangement sequence, the waiting arrangement sequence is used as the drug arrangement sequence, and the process returns to the step of real-time acquisition of daily time. Until no drug data is found in the waiting arrangement sequence, the successful drug warehouses are aggregated to obtain multiple successful drug warehouses, and the failed drug warehouses are aggregated to obtain multiple failed drug warehouses. The number of multiple successful drug warehouses and the number of multiple failed drug warehouses are counted respectively to obtain the number of successes and the number of failures. Based on the multiple successful drug warehouses and the multiple failed drug warehouses, the settlement drug box is confirmed. Multiple medication times are read from the statistical unit, and medication adherence is calculated based on the number of successful doses, the number of failed doses, and the multiple medication times.

3. The method for comprehensive drug treatment management of patients with chronic kidney disease as described in claim 2, characterized in that, The formula for calculating medication adherence is as follows: Where, τ CKD Medication adherence is represented by α (number of successful cases), β (number of failed cases), and t (number of expenditures). i For the i-th medication time among multiple medication times, t max The reminder time threshold is given, and ln is the natural logarithm.

4. The method for comprehensive drug treatment management of patients with chronic kidney disease as described in claim 3, characterized in that, The calculation of drug inappropriateness using patient age, patient weight, adverse reaction set, and patient management database includes: Obtain the adverse reaction sequence, wherein the adverse reaction sequence includes: m adverse reaction numbers; For each adverse reaction group in the adverse reaction set, the following procedures were performed: Adverse reaction numbers that are identical to adverse reaction numbers in the adverse reaction sequence are identified as pending confirmation numbers, and the position of the pending confirmation number in the adverse reaction sequence is used as the adverse reaction position. The adverse reaction coefficient is calculated based on the adverse reaction ranking and the adverse reaction time in the adverse reaction group, using the following formula: Where, p f Here, x represents the adverse reaction coefficient, and t represents the adverse reaction ranking. f This refers to the time of adverse reaction. Summarize the adverse reaction coefficients to obtain n adverse reaction coefficients, and calculate the adverse reaction index based on the n adverse reaction coefficients, where the adverse reaction index is the sum of the n adverse reaction coefficients; Based on the patient's age, an age range is determined. Based on the age range, N reference patient information is retrieved from the patient management database. The reference patient information includes: reference response set, reference weight, and reference age, and the reference age is within the age range. For each of the N reference patient records, perform the following operation: The reference response index is obtained based on the reference response set in the reference patient information. By summing the reference response indices, N reference response indices are obtained; Drug inappropriateness is calculated based on the adverse reaction index, N reference reaction indices, patient age, and patient weight.

5. The method for comprehensive drug treatment management of patients with chronic kidney disease as described in claim 4, characterized in that, The process of determining the age range based on the patient's age includes: The maximum and minimum ages are calculated based on the patient's age and a preset similar age. The maximum age is the sum of the patient's age and the similar age, and the minimum age is the absolute difference between the patient's age and the similar age. An age range is determined based on the maximum and minimum ages, where the maximum age is the maximum age and the minimum age is the minimum age.

6. The method for comprehensive drug treatment management of patients with chronic kidney disease as described in claim 5, characterized in that, The calculation of drug inappropriateness based on adverse reaction index, N reference reaction indices, patient age, and patient weight includes: The target reference index is calculated based on N reference response indices, the patient's age, and the patient's weight, using the following formula: Where, μ x The target reference index is Y0, where Y0 is the patient's age, G0 is the patient's weight, and P is the target reference index. i Y is the i-th reference response index among N reference response indices. i and G i These are the reference age and reference weight corresponding to the i-th reference response index among N reference response indices, where | represents taking the absolute value; Drug inappropriateness is calculated based on the adverse reaction index and the target reference index, using the following formula: Where, μ ID For inappropriate medication, μ x This is the adverse reaction index.

7. The method for comprehensive drug treatment management of patients with chronic kidney disease as described in claim 6, characterized in that, The calculation of state recovery degree and updated average index using basic physical indicators, diagnostic physical indicators, updated basic indicator set, and updated diagnostic indicators includes: The updated mean heart rate, updated mean blood glucose, and updated mean blood pressure are calculated based on the updated basic indicator set. The updated basic indicator set includes multiple updated indicators, and the updated indicators include updated heart rate, updated blood glucose, and updated blood pressure. The updated mean heart rate, updated mean blood glucose, and updated mean blood pressure are the average values ​​of the updated heart rate, updated blood glucose, and updated blood pressure corresponding to the multiple updated indicators, respectively. The updated average indicators are obtained by summarizing and updating the average heart rate, average blood glucose, and average blood pressure. Recovery status is calculated based on basic physical indicators, diagnostic physical indicators, updated average indicators, and updated diagnostic indicators. Basic physical indicators include: basic heart rate, basic blood glucose, and basic blood pressure. Diagnostic physical indicators include: serum creatinine level and parathyroid hormone level. Updated diagnostic indicators include: updated serum creatinine level and updated parathyroid hormone level. The formula for calculating recovery status is shown below: Where, θ ID To indicate recovery status, HR0, BG0, and BP0 represent baseline heart rate, baseline blood glucose, and baseline blood pressure, respectively. and These represent the updated mean heart rate, updated mean blood glucose, and updated mean blood pressure, respectively, among the updated mean indicators. Cr0 and PTH0 represent serum creatinine and parathyroid hormone levels, respectively. x and PTH x These are the refreshed serum creatinine level and the refreshed parathyroid hormone level, respectively, HR best The preset optimal heart rate is defined as a0, the preset serum creatinine weight is b0, and the preset parathyroid hormone weight is b0.

8. The method for comprehensive drug treatment management of patients with chronic kidney disease as described in claim 7, characterized in that, The formula for calculating the treatment success index is as follows: Among them, Tr CKD The success rate index is denoted by e, which is a natural constant.

9. The method for comprehensive drug treatment management of patients with chronic kidney disease as described in claim 8, characterized in that, The process of identifying the target pillbox and target arrangement sequence based on available pillboxes and treatment success index includes: The treatment success index is compared with a preset first treatment threshold and the treatment success index is compared with a preset second treatment threshold, wherein the first treatment threshold is greater than the second treatment threshold; If the treatment success index is greater than or equal to the first treatment threshold, then obtain the health care arrangement sequence, and use the empty medicine box to obtain the health care medicine box, use the health care medicine box as the target medicine box, and use the health care arrangement sequence as the target arrangement sequence; If the treatment success index is greater than or equal to the second treatment threshold and less than the first treatment threshold, then an equivalent medicine box is obtained using the spare medicine box, the equivalent medicine box is used as the target medicine box, and the drug arrangement sequence is used as the target arrangement sequence. If the treatment success index is less than or equal to the second treatment threshold, the adverse reaction set, the updated basic indicator set, and the updated diagnostic indicators are integrated into an arrangement data package. The arrangement data package is sent to the pre-built doctor-patient analysis system to obtain the doctor-patient diagnostic system. Based on the doctor-patient diagnostic system and the available medicine boxes, the updated arrangement sequence and the updated medicine box are obtained. The updated medicine box is used as the target medicine box, and the updated arrangement sequence is used as the target arrangement sequence.

10. A comprehensive drug treatment management system for patients with chronic kidney disease, characterized in that, The system includes: The patient data acquisition module is used to obtain the patient ID and read the kidney disease patient dataset from the pre-built hospital database based on the patient ID. The kidney disease patient dataset includes: patient age, patient weight, patient address, basic physical indicators, diagnostic physical indicators and medication schedule sequence. The time of reading the kidney disease patient dataset is used as the starting point and the time is recorded in real time to obtain the drug treatment time. The smart pillbox monitoring module is used to send pre-built smart medical pillboxes to the patient's address. When the smart medical pillbox is signed for, an operational pillbox is obtained. The operational pillbox includes multiple ordinary pill compartments, and each ordinary pill compartment includes a pill compartment indicator light, a pill compartment number, and a pill compartment window. The medication administration sequence and the operational pillbox are used to obtain medication adherence and billing pillboxes. The billing pillboxes are then recycled to obtain empty pillboxes. The success index calculation module is used to retrieve the adverse reaction set, update the basic indicator set, and update the diagnostic indicators from the pre-built patient management database based on the patient ID. The adverse reaction set includes n adverse reaction groups, and each adverse reaction group includes an adverse reaction number and an adverse reaction time. The module calculates drug inappropriateness using the patient's age, weight, adverse reaction set, and patient management database. It calculates the recovery rate and updates the average indicators using basic physical indicators, diagnostic physical indicators, updated basic indicator set, and updated diagnostic indicators. The module calculates the treatment success index based on medication adherence, drug inappropriateness, and recovery rate. Based on the available medicine boxes and the treatment success index, the module identifies the target medicine box and the target arrangement sequence. The medication management cycle module is used to use the target pillbox as a medical smart pillbox, the target arrangement sequence as a medication arrangement sequence, the updated average index as a basic physical index, and the updated diagnostic index as a diagnostic physical index. It then returns to the step of sending the pre-built medical smart pillbox to the patient's address until the medication treatment time is greater than the preset total treatment time, thus completing the full-course medication treatment management for patients with chronic kidney disease.

Images